Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H1 2015

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Review, H1 2015', provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 11

Therapeutics Development 12

Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Overview 12

Pipeline Products for Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis 13

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Therapeutics under Development by Companies 14

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Therapeutics under Investigation by Universities/Institutes 17

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Products under Development by Companies 22

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Products under Investigation by Universities/Institutes 25

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Companies Involved in Therapeutics Development 26

AnGes MG, Inc. 26

AstraZeneca PLC 27

Bayer AG 28

Biosidus S.A. 29

Biscayne Pharmaceuticals, Inc. 30

Bristol-Myers Squibb Company 31

Cardiome Pharma Corp 32

CardioVascular BioTherapeutics, Inc. 33

Eagle Pharmaceuticals, Inc. 34

Gilead Sciences, Inc. 35

Hemostemix Ltd 36

Human Stem Cells Institute 37

Isis Pharmaceuticals, Inc. 38

Juventas Therapeutics, Inc. 39

Lacer, S.A. 40

Lee's Pharmaceutical Holdings Limited 41

Lonestar Heart, Inc. 42

MedImmune, LLC 43

Merck & Co., Inc. 44

Miltenyi Biotec GmbH 45

Multi Gene Vascular Systems Ltd 46

Nuo Therapeutics, Inc. 47

Pluristem Therapeutics Inc. 48

Regado Biosciences, Inc. 49

The Medicines Company 50

ViroMed Co., Ltd. 51

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Therapeutics Assessment 52

Assessment by Monotherapy Products 52

Assessment by Target 53

Assessment by Mechanism of Action 55

Assessment by Route of Administration 57

Assessment by Molecule Type 59

Drug Profiles 61

ACP-01-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

ALD-201-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

anacetrapib-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Aptamers for Cardiovascular Diseases-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

BAY-606583-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

beperminogene perplasmid-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Biglycan Therapy for Cardiovascular Diseases-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

BIS-5409-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

bivalirudin-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

bivalirudin-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

BQ-123-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

C2 ceramide-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

C6 ceramide-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

cangrelor-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

CAP-1002-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Cryocell-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

CVBT-141H-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Gemacell-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

Gene Therapy to Activate VEGF for Ischemia-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

ISIS-APOARx-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

ISIS-CRPRx-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

JVS-100-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

LA-419-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

MEDI-6012-Drug Profile 97

Product Description 97

Mechanism of Action 97

R&D Progress 97

Monoclonal Antibody to Inhibit CD20 for Cardiovascular Disease-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

MultiGeneGraft-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

MZ-004-Drug Profile 101

Product Description 101

Mechanism of Action 101

R&D Progress 101

Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

Proteins for Ischemic Heart Disease-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

ranolazine ER-Drug Profile 105

Product Description 105

Mechanism of Action 105

R&D Progress 105

rivaroxaban-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

Small Molecule for Coronary Artery Disease-Drug Profile 112

Product Description 112

Mechanism of Action 112

R&D Progress 112

Stem Cell Therapy for Cardiovascular Disease-Drug Profile 113

Product Description 113

Mechanism of Action 113

R&D Progress 113

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 115

Product Description 115

Mechanism of Action 115

R&D Progress 115

Synthetic Peptides to Modulate CD36 Receptor for Ischemic Heart Disease and Macular Degeneration-Drug Profile 117

Product Description 117

Mechanism of Action 117

R&D Progress 117

tirofiban hydrochloride-Drug Profile 119

Product Description 119

Mechanism of Action 119

R&D Progress 119

VM-202-Drug Profile 121

Product Description 121

Mechanism of Action 121

R&D Progress 121

XL-652-Drug Profile 123

Product Description 123

Mechanism of Action 123

R&D Progress 123

ZK-001-Drug Profile 125

Product Description 125

Mechanism of Action 125

R&D Progress 125

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Recent Pipeline Updates 127

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects 155

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Discontinued Products 158

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Product Development Milestones 159

Featured News & Press Releases 159

Nov 14, 2014: The Medicines Company to Present New Data on Investigational Antiplatelet Agent Cangrelor at 2014 AHA Annual Scientific Sessions in Chicago 159

Oct 27, 2014: The Medicines Company Wins Favorable Judgment in Angiomax (Bivalirudin) Patent Litigation 159

Oct 06, 2014: Capricor Announces Plans to Pursue Clinical Program for the Treatment of Duchenne Muscular Dystrophy With Cardiosphere-Derived Cells (CDCs) 160

Sep 02, 2014: Isis Pharmaceuticals Presents Data On ISIS-APO(A)RX At European Society of Cardiology Congress 2014 160

Jul 07, 2014: The Medicines Company Receives Market Authorization Renewal for Angiox (Bivalirudin) from the European Medicines Agency and the European Commission 161

Apr 28, 2014: The Medicines Company Files Petition Against Aurobindo Over Patent Infringement 162

Mar 30, 2014: Analysis of EUROMAX and HORIZONS-AMI Trials of The Medicines Company's Angiomax Presented at ACC.14 162

Dec 23, 2013: European Medicines Agency Accepts Marketing Authorization Application for The Medicines Company's Cangrelor 163

Oct 11, 2013: Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT 164

Oct 09, 2013: First Patient Enrolled in Phase III Trial Evaluating The Medicines Company's Angiomax in Patients Undergoing Peripheral Endovascular Procedures 164

Appendix 166

Methodology 166

Coverage 166

Secondary Research 166

Primary Research 166

Expert Panel Validation 166

Contact Us 167

Disclaimer 167

List of Tables

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 12

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 15

Number of Products under Development by Companies, H1 2015 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Development, H1 2015 20

Comparative Analysis by Unknown Stage Development, H1 2015 21

Products under Development by Companies, H1 2015 22

Products under Development by Companies, H1 2015 (Contd..1) 23

Products under Development by Companies, H1 2015 (Contd..2) 24

Products under Investigation by Universities/Institutes, H1 2015 25

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by AnGes MG, Inc., H1 2015 26

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by AstraZeneca PLC, H1 2015 27

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Bayer AG, H1 2015 28

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Biosidus S.A., H1 2015 29

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Biscayne Pharmaceuticals, Inc., H1 2015 30

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Bristol-Myers Squibb Company, H1 2015 31

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Cardiome Pharma Corp, H1 2015 32

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by CardioVascular BioTherapeutics, Inc., H1 2015 33

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 34

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Gilead Sciences, Inc., H1 2015 35

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Hemostemix Ltd, H1 2015 36

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Human Stem Cells Institute, H1 2015 37

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 38

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Juventas Therapeutics, Inc., H1 2015 39

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Lacer, S.A., H1 2015 40

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 41

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Lonestar Heart, Inc., H1 2015 42

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by MedImmune, LLC, H1 2015 43

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Merck & Co., Inc., H1 2015 44

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Miltenyi Biotec GmbH, H1 2015 45

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 46

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Nuo Therapeutics, Inc., H1 2015 47

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Pluristem Therapeutics Inc., H1 2015 48

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by Regado Biosciences, Inc., H1 2015 49

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by The Medicines Company, H1 2015 50

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Pipeline by ViroMed Co., Ltd., H1 2015 51

Assessment by Monotherapy Products, H1 2015 52

Number of Products by Stage and Target, H1 2015 54

Number of Products by Stage and Mechanism of Action, H1 2015 56

Number of Products by Stage and Route of Administration, H1 2015 58

Number of Products by Stage and Molecule Type, H1 2015 60

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics-Recent Pipeline Updates, H1 2015 127

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects, H1 2015 155

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects (Contd..1), H1 2015 156

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Dormant Projects (Contd..2), H1 2015 157

Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Discontinued Products, H1 2015 158

List of Figures

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2015 12

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)-Comparative Analysis, H1 2015 13

Number of Products under Development by Companies, H1 2015 14

Number of Products under Investigation by Universities/Institutes, H1 2015 17

Comparative Analysis by Late Stage Development, H1 2015 18

Comparative Analysis by Clinical Stage Development, H1 2015 19

Comparative Analysis by Early Stage Products, H1 2015 20

Assessment by Monotherapy Products, H1 2015 52

Number of Products by Top 10 Targets, H1 2015 53

Number of Products by Stage and Top 10 Targets, H1 2015 53

Number of Products by Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 55

Number of Products by Top 10 Routes of Administration, H1 2015 57

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 57

Number of Products by Top 10 Molecule Types, H1 2015 59

Number of Products by Stage and Top 10 Molecule Types, H1 2015 59

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AnGes MG, Inc.

AstraZeneca PLC

Bayer AG

Biosidus S.A.

Biscayne Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Cardiome Pharma Corp

CardioVascular BioTherapeutics, Inc.

Eagle Pharmaceuticals, Inc.

Gilead Sciences, Inc.

Hemostemix Ltd

Human Stem Cells Institute

Isis Pharmaceuticals, Inc.

Juventas Therapeutics, Inc.

Lacer, S.A.

Lee's Pharmaceutical Holdings Limited

Lonestar Heart, Inc.

MedImmune, LLC

Merck & Co., Inc.

Miltenyi Biotec GmbH

Multi Gene Vascular Systems Ltd

Nuo Therapeutics, Inc.

Pluristem Therapeutics Inc.

Regado Biosciences, Inc.

The Medicines Company

ViroMed Co., Ltd.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutic Products under Development, Key Players in Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Overview, Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline, Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com